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ABSTRACT. We worked toward developing a core outcome set for clinical research studies in polymyalgia
rheumatica (PMR) by conducting (1) patient consultations using modified nominal group technique;
(2) a systematic literature review of outcome measures in PMR; (3) a pilot observational study of
patients presenting with untreated PMR, and further discussion with patient research partners; and
(4) a qualitative focus group study of patients with PMR on the meaning of stiffness, using thematic
analysis. (1) Consultations included 104 patients at 4 centers. Symptoms of PMR included pain,
stiffness, fatigue, and sleep disturbance. Function, anxiety, and depression were also often
mentioned. Participants expressed concerns about diagnostic delay, adverse effects of glucocorti-
coids, and fear of relapse. (2) In the systematic review, outcome measures previously used for PMR
include pain visual analog scores (VAS), morning stiffness, blood markers, function, and quality of
life; standardized effect sizes posttreatment were large. (3) Findings from the observational study
indicated that asking about symptom severity at 7 AM, or “on waking,” appeared more relevant to
disease activity than asking about symptom severity “now” (which depended on the time of
assessment). (4) Preliminary results were presented from the focus group qualitative study, encom-
passing broad themes of stiffness, pain, and the effect of PMR on patients’ lives. It was concluded
that further validation work is required before a core outcome set in PMR can be recommended.
Nevertheless, the large standardized effect sizes suggest that pain VAS is likely to be satisfactory as
a primary outcome measure for assessing response to initial therapy of PMR. Dissection of
between-patient heterogeneity in the subsequent treatment course may require attention to comor-
bidity as a potential confounding factor. (First Release Feb 1 2014; J Rheumatol 2014;41:819–23;
doi:10.3899/jrheum.131254)
Key Indexing Terms:
POLYMYALGIA RHEUMATICA                             OUTCOME AND PROCESS ASSESSMENT
OMERACT                          PAIN                           STIFFNESS CORE SET
From UK National Institute for Health Research (NIHR)-Leeds
Biomedical Research Unit, Leeds Institute of Rheumatic and
Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of
Rheumatology, University Hospitals Leuven, Leuven, Belgium;
Rheumatology Department, Centro Hospitalar e Universitário de
Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell
Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford
and St Peter’s Hospitals National Health Service (NHS) Foundation Trust,
Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of
Health and Life Sciences, University of the West of England, Bristol;
Department of Rheumatology, Leeds Teaching Hospitals NHS Trust,
Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston,
Massachusetts, USA; Department of Rheumatology, Katholieke
Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit,
University of Bristol, Bristol Royal Infirmary, Bristol, UK.
S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit,
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of
Leeds; S. Arat, RN, MSc, Department of Rheumatology, University
Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department,
Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA
UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford
and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre
for Health and Clinical Research, Faculty of Health and Life Sciences,
University of the West of England; C.T. Pease, MD, FRCP, Department of
Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD,
FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG
LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s
Hospitals NHS Foundation Trust; R. Westhovens, Department of
Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan,
Academic Rheumatology Unit, University of Bristol, Bristol Royal
Infirmary.
Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit,
Bristol Royal Infirmary, Bristol, BS2 8HW, UK. 
E-mail: john.kirwan@bristol.ac.uk
Polymyalgia rheumatica (PMR) is a common inflammatory
disease with a lifetime risk estimated at 2.4% for women
and 1.7% for men1. Untreated, PMR can cause profound
disability2. Diagnosis relies on clinical acumen and is
supported by a rapid response to low- to medium-dose
glucocorticoid therapy; therefore, it is essential that
response to glucocorticoids is precisely defined3. Further,
there is substantial variation in time to cessation of gluco-
corticoid therapy4, only part of which can be explained by
pretreatment inflammatory markers. PMR may be more
heterogeneous than is commonly supposed. Work carried
out by the European League Against Rheumatism
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(EULAR) working group on glucocorticoids underlines the
potential morbidity incurred by patients taking these
medications. In PMR, the evidence for efficacy of any
treatment other than glucocorticoid remains very limited5;
further progress in this area requires development of a
consensus on important core outcomes for use in clinical
trials of PMR3. 
A Patient’s Experience of Polymyalgia Rheumatica
When I was first feeling the effects of polymyalgia
rheumatica (PMR), I naively believed that I would be
able to tell my doctor all about my suffering; he would
prompt me with relevant questions, which would lead
to either a correct diagnosis and treatment or a referral
to an expert in the right field; I would be told all about
the drugs I may have to take and what side effects I
could expect. However, I was sadly disillusioned in a
very short time. Confused, I started to see if I could find
fellow sufferers to swop stories with and get advice
from on what to do and where to turn. They all had a
story but the differences in their experiences were huge.
It turned out that I was lucky, I was diagnosed and given
prednisolone within a month of the first signs, but I
talked to people who were in severe pain for a year or
more, were told they had a few months to live, had their
homes converted with stair lifts and hoists fitted, were
unnecessarily given huge amounts of prednisolone, or
were hospitalized. They would list their different
experiences of prednisolone: “side effects” of the drug;
the amount they had been taking; the (seemingly
arbitrary) changes in dose. Some had ideas about alter-
native therapies and diets that they believed to be
beneficial. 
There seems to be little evidence as to which set of
criteria (if any) provides a reliable diagnosis of PMR,
nor which treatment regimen is most appropriate. The
devastating impact PMR might have on a person’s life
is not appreciated, nor is the importance of a wide range
of symptoms produced by PMR. It is very important for
patients to feel confident that proven methods of
diagnosis and treatment are being used and that they are
being listened to: Otherwise additional stress and worry
further impairs recovery. I believe that what we are
involved with in this group will go a long way to
improving the lot of the PMR sufferer.
1. Outcomes of Importance to Patients
In the process of planning the formal research that would be
needed to define a core set of outcome measures in PMR,
we started by consulting patients. In this preliminary,
“scoping” consultation exercise, we used a modified
nominal group technique. We invited clinic patients, who
were either currently taking or had recently stopped taking
glucocorticoids, to talk to us in informal discussion groups,
each facilitated by a healthcare professional with relevant
knowledge of PMR. This was done at 3 centers in the UK
(Bristol, Leeds, Chertsey) and 1 in Belgium. At one of the
UK centers (Chertsey), an anonymous postal survey was
also conducted in which patients were asked to list issues of
importance in their experience of PMR. 
Within each discussion group, participants were asked to
consider, in turn, symptoms, diagnosis, and treatment. The
statements recorded by a facilitator during the group
discussion were then provided to each patient and each then
selected the 10 statements most important to them
personally. This was a pragmatic way of ensuring that
patients had time to reflect on the points raised during the
discussion, and were able to anonymously record which
were important to them, without disclosing to others. It also
provided an anonymous record of issues raised by the
discussion groups, serving as a starting point for us to
consider what had emerged and plan more formal research
as part of the Outcome Measures in Rheumatology
(OMERACT) process. This process started at a study group
meeting at the EULAR 2011 meeting and has continued by
e-mail and teleconference subsequently. 
In all, 104 patients with PMR were involved; because
this was not a formal research study, we did not collect data
about the participants themselves, such as age, sex, or
treatment duration. However, some common issues arose
across more than 1 center and these are now discussed. As a
first approach to grouping them, we classified them under
headings of the World Health Organization International
Classification of Functioning, Disability and Health
(WHO-ICF)6. 
Impairments. Symptoms, or “impairment” in WHO-ICF6,
were clearly important to patients. Pain, stiffness, fatigue,
and sleep disturbance were very often mentioned. Some
patients said, “The stiffness is so bad, it is pain,” suggesting
that for some the 2 words pain and stiffness may not always
represent separate constructs. This idea has been suspected
by others and potentially challenges many traditional
assumptions about PMR7. We felt that formal qualitative
research would be valuable to define exactly what patients
with PMR mean by stiffness, which is the cardinal symptom
in this disease. The concepts of “morning stiffness” and
“early morning stiffness,” although an essential part of the
physician’s diagnostic process to discriminate inflammatory
from noninflammatory musculoskeletal symptoms, were
rarely volunteered by patients using those words during
group discussions unless specifically prompted. However,
patients did have variation in their symptoms over the day. 
Activities.Ability to perform activities of daily living, and to
remain independent on all levels, appeared of great impor-
tance to patients. Indeed, many patients found it easier to
describe what they could not do, than to describe the actual
symptoms that prevented them from doing things. Getting
out of bed and turning over in bed were frequently
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mentioned, but patients also mentioned activities such as
getting up from the floor, getting off the sofa or the toilet,
driving, picking things up from the floor, opening doors,
walking, or dressing. The Health Assessment Questionnaire
(HAQ) Disability Index, a widely used measure of dis-
ability8, may capture many of these aspects of activity. 
Participation. Not many patients reported problems with
participating in work or other social roles. This may relate to
the age group of patients with PMR and the context of the
discussions, and highlighted the need for further work
exploring the nature of the effect of PMR symptoms,
diagnosis, and treatment on patients’ lives. Participation
might be influenced by many factors including fatigue
(reported by many patients), which is an important factor for
other rheumatic conditions9,10. Anxiety and depression were
mentioned by some patients; it may be worthwhile to use a
standard instrument, such as the Hospital Anxiety and
Depression Scale, in research studies and perhaps in clinical
practice11.
Diagnosis and treatment. Regarding diagnosis, the
overwhelming message from our patients was that the time
taken to reach a diagnosis was very important to them. As
these patients were all self-recruited from secondary care,
however, they may represent a more difficult-to-diagnose
subset of patients. Conversely, glucocorticoid (steroid)
treatment was frequently referred to as like “magic” or “a
miracle,” often with an effect within 3 days. Some patients
mentioned a “steroid high” or a burst of energy that later
“wore off.”
Patients told us that as treatment went on they had
increasing concern over known and potential side effects of
glucocorticoids. Concerns expressed by patients often
related to changes in physical appearance, including
bruising, skin changes, change in facial shape, hirsutism,
and thinning of scalp hair. Patients were also concerned
about delayed wound healing, high blood sugar levels, and
osteoporosis. Patients were concerned about the need to take
extra tablets to reduce the risk of steroid-related complica-
tions. Fear of relapse and difficulty managing the steroid
dose reduction were described as important for some
patients. Patients sometimes found it hard to tell whether
some of their ongoing symptoms (such as sweating) were
due to the PMR or the glucocorticoid treatment, or were
simply the effects of age or comorbidities. 
A common theme was patients’ requirement for infor-
mation, and for their treating physicians to be well-informed
about the disease, both in primary and secondary care. For
example, patients at 1 center said that they had been worried
that doing sport or physical exercise might be damaging,
and that it was important to them to be reassured that
physical activity was not harmful in PMR. The value of a
multidisciplinary approach was emphasized; the family
physician, hospital specialist, and nurse-led advice lines
were all specifically mentioned and patients expressed a
need for clear directions as to how to reduce their glucocor-
ticoid dose. 
In response to the messages arising from this conver-
sation with patients, the OMERACT PMR Outcomes
Working Group was formed. We feel it is worthwhile
documenting these informal consultations with patients to
make explicit our participatory approach, central to the
OMERACT philosophy, in which patients are involved as
partners at all stages of research12,13. We initiated 3 studies
that were briefly reported at the OMERACT PMR Special
Interest Group (SIG).
2. Literature Review of Outcome Measures Used in
Studies of PMR
C. Duarte reported on a systematic literature review of
outcome measures used in studies of PMR, on behalf of
herself and J. da Silva. Of 623 articles screened, 8 observa-
tional studies and 13 controlled trials met the selection
criteria. Pain was recorded as an outcome in 11. Of these, 6
used a visual analog scale (VAS) with no defined stem
question or anchors, and the remainder used differently
named grades. “Morning stiffness” was recorded in 10, but
there was no consistency about how this was defined or
collected. Blood markers of inflammation (erythrocyte
sedimentation rate and C-reactive protein) were nearly
always recorded. A few studies measured function (using the
HAQ2,14) and 1 observational study assessed health-related
quality of life using the Medical Outcome Study Short Form
Health Survey 362. The main conclusion was that, although
standardized effect sizes following treatment were large (2.5
to 6.5), these studies used nonspecific instruments; there
was a lack of consensus on definitions; and there was poor
evidence of validity.
3. Pilot Work on Measuring Symptoms and Function in
PMR
S. Mackie and C.T. Pease described pilot work on
measuring symptoms and function in PMR. Ethical
approval was obtained (MREC 09/H1307/98 and MREC
05/Q1108/28) and patients gave informed consent. Patients
presenting to clinic with untreated PMR (n = 23) were
assessed using outcome measures arbitrarily selected from
the literature. Patients tended to give higher pain and
stiffness VAS scores if asked specifically about pain at 7
AM or on waking, rather than referring to pain “now” at the
moment of completion of the questionnaire. 
Because of this finding, patients were also asked about
their function in the morning and evening; about half the
patients reported better function in the evening than the
morning, although function often remained impaired all day.
Further discussion with patient research partners about the
face validity of HAQ in PMR revealed that almost all the
items in the HAQ had potential relevance to activities
affected by PMR.
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4. Qualitative Study
R. Hughes described a multicenter study on the meaning of
stiffness for patients with PMR. Ethical approval was
obtained (REC 12/LO/0120) and participants provided
informed consent. Eight focus group discussions were held,
each involving 6 to 8 patients with PMR. Discussions were
guided by the same set of broad introductory questions,
recorded, transcribed, and analyzed by formal qualitative
methods using thematic analysis15. A full report is being
prepared, but saturation of themes was achieved, and
progress is being made toward explicitly defining stiffness
in PMR and its relationship to pain. Further, inductive
analyses also saw themes emerging about the effect of PMR
on participants’ lives.
Discussions at the OMERACT PMR SIG
Potential new opportunities to improve the treatment of
PMR16 make the definition of appropriate outcome
measures a pressing need. From an industry perspective,
outcomes used to support labeling claims need to meet the
criteria laid down by regulatory bodies such as the US Food
and Drug Administration17. Typically 2 well-controlled
clinical trials each with p < 0.05 for a single indication are
required for drug licensing using accepted primary efficacy
endpoints (e.g., the American College of Rheumatology
20% response criterion for rheumatoid arthritis); and any
patient-reported outcome measures used in a study must be
adequately validated. From this perspective, the VAS for
pain would be acceptable. 
While “stiffness” clearly emerged as an important
outcome from the patient perspective, the proper wording to
use and the distinction of stiffness from pain requires clari-
fication. Both stiffness and pain had high effect sizes, so that
the primary outcome measure of pain would be adequate
while other outcomes such as stiffness and function (and
blood inflammatory markers) could remain as secondary or
exploratory. The importance of assessing comorbidity as
potential confounders of measures of pain and stiffness was
also discussed. The preliminary work on HAQ suggests that
HAQ is probably adequate to measure functional change in
response to therapy.
A broader view of the published studies and what
happens to the outcome measures in the longer term led to
the suggestion that there may be a very large initial effect
size of treatment with prednisone 15 mg daily, but that
subsequently there is a “tail” of symptoms that persists in
some patients. Whether these symptoms in treated patients
are due to uncontrolled disease, or comorbid conditions that
can also cause pain and stiffness, is unclear. It is possible
that this “tail” phenomenon might be due to heterogeneity
within the group, in that a small number of patients with
poor response to treatment might affect the summary
statistics for the whole patient group. This could be explored
in future data analysis. Overall, the view of the SIG partici-
pants was that there are sufficient data on the main outcomes
discussed above to allow the design of randomized
controlled trials in PMR using pain VAS as the primary
outcome measure but also measuring stiffness.
In recommending outcome measures for clinical trials of
patients with untreated PMR, the large standardized effect
sizes observed with initial therapy for PMR suggest that
pain VAS is likely to be satisfactory as a primary outcome
measure for assessing response to initial therapy. Issues
raised by patients as key concerns also included delay to
diagnosis, and fear of glucocorticoid adverse effects and/or
disease relapse. 
In recommending outcome measures for longitudinal
observational studies, attention should be given to possible
heterogeneity in reasons for the ongoing “tail” of symptoms,
and the potential confounding role of comorbidity. 
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